Archive: 2022

CHDI's 17th Annual Therapeutics Conference: The Future of Huntington's Research

CHDI’s 17th Annual Therapeutics Conference: Event ReviewBy Ronald Ramos (Senior Director, Business Development) and Kirsi Kinnunen (Senior Biomarker Scientist) CHDI’s 17th Annual HD Therapeutics Conference finally returned to a full, in-person event for the first time since 2020.

GAP-Net Site Optimization Conference 2022: Event Review

The Global Alzheimer's Platform Foundation’s GAP-Net Site Optimization Conference 2022 gave all participants an update on the important Bio-Hermes trial which is going very well. This year’s conference was a highly collaborative event with many interesting presentations and discussions on issues related to research in Alzheimer’s Disease.

IXICO & GAP Foundation: Alzheimer’s & The Bio-Hermes Study

Interview with IXICO & GAP Foundation: Alzheimer’s Disease & the Pioneering Bio-Hermes StudyAlzheimer's disease is an irreversible, progressive brain disorder that accounts for about 50–75% of all cases of dementia. It’s a growing problem. The USA saw a 145% increase in Alzheimer’s disease-related deaths between 2000 and 2018.

Discover IXIQ.Ai | IXICO's AI-Based Brain Segmentation Platform

What is IXIQ. Ai? Find out from our Chief Scientific Officer Robin WolzThis month, we launch into production on its first clinical trials. IXIQ. Ai is the next generation of our technology platform which we have been developing for more than a decade.